Signal from the log
Altay Therapeutics
37 M$ · Series A · United States · Biotech
Altay Therapeutics développe DX5057, un comprimé qui bloque DUX4, la protéine dont l'expression anormale détruit le muscle dans la dystrophie FSHD. La série A est codirigée par Sound Bioventures et HealthCap, et la première étude chez l'humain est prévue au premier trimestre 2027.
Verified
Announced on , logged by the watch of 14 October 2026.
- Operation
- Funding round
- Announced amount
- 37 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Sound Bioventures , HealthCap , with Fountain Healthcare Partners , Biogen New Ventures , Pappas Capital , Global BioAccess Fund
Provenance
Source businesswire
Logged on 14 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.